Rebecca Nagy on PIK3CA Inhibitors: How did the blood and tissue results compare?

Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor.

Read here: https://www.globenewswire.com/news-release/2020/04/09/2014287/0/en/Study-Shows-Guardant360-Test-Identifies-Predictors-of-Response-to-PIK3CA-Inhibitors-in-Women-with-HR-Metastatic-Breast-Cancer.html